Long-Term Clinical and Radiographic Outcomes of Meniscus Allograft Transplant.

Autor: Phillips AR; Chicago, USA., Haneberg EC; Chicago, USA., Boden SA; Chicago, USA., Yanke AB; Chicago, USA. adam.yanke@rushortho.com., Cole BJ; Chicago, USA.
Jazyk: angličtina
Zdroj: Current reviews in musculoskeletal medicine [Curr Rev Musculoskelet Med] 2024 Sep; Vol. 17 (9), pp. 343-352. Date of Electronic Publication: 2024 Jun 18.
DOI: 10.1007/s12178-024-09904-z
Abstrakt: Purpose of Review: To reduce pain, improve function and possibly mitigate the risk for development of osteoarthritis in patients with functionally deficient meniscus pathology, meniscal allograft transplantation (MAT) can be used to restore native joint biomechanics and increase knee joint longevity. This review explores the senior author's preferred bridge-in-slot technique and recently published long-term clinical and radiographic outcomes following MAT.
Recent Findings: Recent literature demonstrates MAT to be a safe and largely successful procedure for patients with functional meniscus deficiency. A majority of patients reach established minimal clinically important difference (MCID) values. Graft survivorship is approximately 80% at 10 years, significantly delaying and in some cases, preventing the need for future joint reconstruction procedures in these young patients. Return to sport rates are over 70%, revealing meniscal allografts can withstand high impact activities. Cartilage damage at the time of MAT increases the risk for graft and clinical failure, though this may be mitigated with a concomitant cartilage restoration procedure. Meniscal allograft transplantation can provide a durable and effective long-term solution to meniscal deficiency in symptomatic patients who wish to decrease the risk of symptomatic progression and possibly further osteoarthritis and continue activities of daily life and sports with less pain and more function. By restoring more normal joint biomechanics, MAT can mitigate the potential need for future knee arthroplasty in this young active patient population.
(© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: